Results 1 - 10 of 17 : 1 2 Next
Drugmaker Isis must complete cancer tests before submitting its marketing application.
Headache Over for Pozen and Glaxo?
The duo's FDA headache is over, but a new one is about to begin.
Upsetting the agency that approves drugs is never a good move.
FDA approval of a combination drug doesn't leave Merck trembling.
Headache Almost Over for Pozen
The drug is safe; hopefully that's all the FDA wanted to know.
Pozen plans a just-in-case safety trial.
Wednesday's Worst Stocks in the World
It had to be some company.
Will Pozen's response to its second approvable letter be enough?
More Than Momentum: Stocks Rising for a Reason
Sorting a real growth story from a flash in the pan.
Stricter standards at the FDA could create a Foolish opportunity.